Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine
Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine (reported by Reuters)
Sanofi
Sanofi (NASDAQ: SNY; Euronext: SAN) is a global biopharmaceutical company with major franchises in immunology (Dupixent, partnered with Regeneron), vaccines (Beyfortus, Fluzone, Dengvaxia), rare disease (Genzyme-legacy Pompe, Fabry, MS), and a growing oncology pipeline. Sanofi has been reshaping its R&D portfolio toward immunology and rare disease while spinning off its consumer health unit.
Company Info
Sector:Diversified Biopharmaceuticals
Headquarters:Paris, France
Founded:1973
Website:www.sanofi.com/en
Recent News
Sanofi unit in Ireland dinged by FDA on Altuviiio production
Sanofi unit in Ireland dinged by FDA on Altuviiio production. (Fierce Pharma.)
Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies
Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies — Endpoints News coverage of biopharma industry developments.
Sanofi R&D leader Houman Ashrafian to depart, Paulo Fontoura to take the reins
Sanofi's head of R&D Houman Ashrafian will leave the company, with Paulo Fontoura tapped to succeed him as Sanofi reshapes its research leadership.
Sofinnova, Sanofi alum unveil Bionyra with $165M and next-gen immunology assets
Formed by Sofinnova Partners and former Sanofi executive Frédéric Marrache, Bionyra Pharma emerged from stealth Monday with an initial focus in inflammatory bowel disease and atopic dermatitis.
Leadership Team
Belén Garijo
Chief Executive Officer
Careers & Job Openings